Perceptive Advisors LLC Takes $53.81 Million Position in Invivyd, Inc. $IVVD

Perceptive Advisors LLC acquired a new position in shares of Invivyd, Inc. (NASDAQ:IVVD) in the 4th quarter, Holdings Channel.com reports. The fund acquired 21,785,166 shares of the company’s stock, valued at approximately $53,809,000. Perceptive Advisors LLC owned 0.09% of Invivyd at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IVVD. BVF Inc. IL purchased a new stake in Invivyd in the 4th quarter valued at approximately $48,227,000. RA Capital Management L.P. purchased a new stake in Invivyd in the 3rd quarter valued at approximately $18,831,000. ADAR1 Capital Management LLC purchased a new stake in Invivyd in the 3rd quarter valued at approximately $8,108,000. Janus Henderson Group PLC lifted its stake in Invivyd by 28.2% in the 4th quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after buying an additional 7,160,065 shares in the last quarter. Finally, Eventide Asset Management LLC purchased a new stake in Invivyd in the 4th quarter valued at approximately $14,349,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Stock Up 4.4%

Shares of NASDAQ:IVVD opened at $0.93 on Thursday. The company has a market capitalization of $274.34 million, a price-to-earnings ratio of -3.00 and a beta of 0.63. The company has a 50 day moving average of $1.29 and a two-hundred day moving average of $1.74. Invivyd, Inc. has a 52-week low of $0.48 and a 52-week high of $3.07.

Invivyd (NASDAQ:IVVD) last posted its earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The firm had revenue of $13.74 million for the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. On average, equities analysts anticipate that Invivyd, Inc. will post -0.5 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IVVD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research note on Monday. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research note on Tuesday, June 9th. Finally, Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Invivyd currently has a consensus rating of “Hold” and an average target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.